中华创伤杂志(英文版)2024,Vol.27Issue(1) :27-33.DOI:10.1016/j.cjtee.2023.06.003

Association of ABCB1 gene polymorphisms rs1128503,rs2032582,rs4148738 with anemia in patients receiving dabigatran after total knee arthroplasty

Alina Kasimova Dmitry Labutin Anton Gvozdetsky Svetlana Bozhkova
中华创伤杂志(英文版)2024,Vol.27Issue(1) :27-33.DOI:10.1016/j.cjtee.2023.06.003

Association of ABCB1 gene polymorphisms rs1128503,rs2032582,rs4148738 with anemia in patients receiving dabigatran after total knee arthroplasty

Alina Kasimova 1Dmitry Labutin 2Anton Gvozdetsky 3Svetlana Bozhkova2
扫码查看

作者信息

  • 1. Division of Wound Infection Prevention and Treatment,Vreden National Medical Research Center of Traumatology and Orthopaedics,St.Petersburg,Russian Federation;Department of Clinical Pharmacology and Evidence-based Medicine,Pavlov First Saint Petersburg State Medical University,St.Petersburg,Russian Federation
  • 2. Division of Wound Infection Prevention and Treatment,Vreden National Medical Research Center of Traumatology and Orthopaedics,St.Petersburg,Russian Federation
  • 3. Department of Psychiatry and Addictology,North-Western State Medical University named after I.I.Mechnikov,St.Petersburg,Russian Federation
  • 折叠

Abstract

Purpose:Dabigatran is usually prescribed in recommended doses without monitoring of the blood coagulation for the prevention of venous thromboembolism after joint arthroplasty.ABCB1 is a key gene in the metabolism of dabigatran etexilate.Its allele variants are likely to play a pivotal role in the occurrence of hemorrhagic complications.Methods:The prospective study included 127 patients with primary knee osteoarthritis undergoing total knee arthroplasty.Patients with anemia and coagulation disorders,elevated transaminase and creatinine levels as well as already receiving anticoagulant and antiplatelet therapy were excluded from the study.The association of ABCB1 gene polymorphisms rs1128503,rs2032582,rs4148738 with anemia as the outcome of dabigatran therapy was evaluated by single-nucleotide polymorphism analysis with a real-time polymerase chain reaction assay and laboratory blood tests.The beta regression model was used to predict the effect of polymorphisms on the studied laboratory markers.The probability of the type 1 error(p)was less than 0.05 was considered statistically significant.BenjaminiHochberg was used to correct for significance levels in multiple hypothesis tests.All calculations were performed using Rprogramming language v3.6.3.Results:For all polymorphisms there was no association with the level of platelets,protein,creatinine,alanine transaminase,prothrombin,international normalized ratio,activated partial thromboplastin time and fibrinogen.Carriers of rs1128503(TT)had a significant decrease of hematocrit(p=0.001),red blood count and hemoglobin(p=0.015)while receiving dabigatran therapy during the postoperative period compared to the CC,CT.Carriers of rs2032582(TT)had a significant decrease of hematocrit(p=0.001),red blood count and hemoglobin(p=0.006)while receiving dabigatran therapy during the postoperative period compared to the GG,GT phenotypes.These differences were not observed in car-riers of rs4148738.Conclusion:It might be necessary to reconsider thromboprophylaxis with dabigatran in carriers of rs1128503(TT)or rs2032582(TT)polymorphisms in favor of other new oral anticoagulants.The long-term implication of these findings would be the reduction of bleeding complications after total joint arthroplasty.

Key words

Thromboprophylaxis/P-glycoprotein/Dabigatran/Anemia/SNPs

引用本文复制引用

基金项目

Vreden National Medical Research Center of Traumatology and Orthopaedics()

出版年

2024
中华创伤杂志(英文版)
中华医学会

中华创伤杂志(英文版)

CSTPCDCSCD
影响因子:0.608
ISSN:1008-1275
参考文献量38
段落导航相关论文